Genmab A/S

NASDAQ:GMAB

Biotechnology

Healthcare
$50.97 -0.47%

-$0.12 today

Market cap
$31.43B
Beta
0.68
P/E (TTM)
18.7
EPS (TTM)
$13.36
52W Low $20.23High $35.43

Volume 2.96M

Average 1.85M

GMAB Total Assets

Everything the company owns or controls; equal to total liabilities plus equity.

Genmab A/SNASDAQ: GMAB

Total Assets · Q2 FY2026 · quarter ended Jun 2026

Total assets rises 93.7% from a year ago

Total assets stood at $12.52B at the end of Q2 FY2026, up 93.7% from a year earlier and up 1.1% from the prior quarter. Over 3 fiscal years it compounded at -24.7% a year.

Context

  • Total assets increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether total assets keeps rising in the next quarterly balance sheet after a +93.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$12.52B+1.1% QoQ
Last fiscal yearDec 2025
$12.84B-72.0% YoY
Year agoJun 2025
$6.46B+93.7% since
Total Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+93.7%——
1 year-72.0%——
3-year CAGR-24.7%——
5-year CAGR——
10-year CAGR——

Total Assets history

Mixed currencies · from the balance sheet

Latest · FY2025
12.84B USD
Year-over-year change
—

Total Assets vs competitors

How GMAB compares with its peers on the latest reported figures

  • Peers report in different currencies, so total assets is compared through growth and rates rather than absolute size.
  • Its year-over-year change of +93.7% is the highest of 11, against a peer median of +2.6%.
  • Over three fiscal years its annual growth of -24.7% compares with a peer median of -2.2%.
GMAB Competitors
Total Assets for GMAB and competitors
Company Period Latest balance YoY 3-year CAGR
BNTXBioNTech SEJun 2026€20.33B EUR-6.0%-1.9%
GMABGenmab A/SJun 2026$12.52B USD+93.7%-24.7%
INCYIncyte CorporationJun 2026$7.87B USD+35.2%+6.0%
EXELExelixis, Inc.Jul 2026$2.49B USD-6.9%-2.5%
LEGNLegend Biotech CorporationSep 2026$1.68B USD-1.8%+9.2%
IOVAIovance Biotherapeutics, Inc.Sep 2026$991.21M USD+9.5%+11.2%
RCUSArcus Biosciences, Inc.Jun 2026$924M USD-14.0%-5.4%
ADCTADC Therapeutics S.A.Mar 2026$291.5M USD+7.0%-13.0%
MGNXMacroGenics, Inc.Mar 2026$217.87M USD-3.0%-3.9%
ALXOALX Oncology Holdings Inc.Mar 2026$178.33M USD+47.5%-42.2%
CGENCompugen Ltd.Mar 2026$145.86M USD+26.3%+18.5%
Peer median (excluding GMAB) —+2.6%-2.2%

Competitors are the stored peer set for GMAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

Mixed currencies
Metric
FY2021
Dec 2021 · DKK
FY2022
Dec 2022 · DKK
FY2023
Dec 2023 · DKK
FY2024
Dec 2024 · DKK
FY2025
Dec 2025 · USD
Cash & Equivalents8.96B9.89B14.87B9.86B1.71B
Short-term Investments10.38B12.43B13.27B11.24B0
Net Receivables3.37B5.71B4.95B6.69B1.15B
Inventory0057M62M17.96M
Other Current Assets31M182M003
Total Current Assets22.74B28.22B33.14B27.85B2.88B
Property, Plant & Equipment (Net)975M1.32B1.64B263.83M279.36M
Goodwill0002.54B354.19M
Intangible Assets254M146M101M12.34B9.1B
Long-term Investments371M133M134M228M58.87M
Tax Assets00212M126.68M170.61M
Other Non-current Assets291M300M62M2.46B4
Total Non-current Assets1.89B1.9B2.15B17.96B9.97B
Total Assets24.63B30.12B35.29B45.81B12.84B
Account Payables350M0001.07B
Short-term Debt0000273M
Tax Payables0054M1.71B0
Deferred Revenue0033M24M23.95M
Other Current Liabilities860M1.75B00(663.92K)
Total Current Liabilities1.57B1.82B2.48B5.31B1.42B
Long-term Debt00005B
Deferred Tax Liabilities0002.36B363.17M
Deferred Revenue (Non-current)00480M480M94.78M
Other Non-current Liabilities500M491M35M30M5M
Total Non-current Liabilities863M1.01B1.2B3.81B5.59B
Total Liabilities2.43B2.84B3.68B9.11B7.01B
Common Stock66M66M66M66M9.98M
Retained Earnings10.02B14.81B19.02B23.55B4.09B
Accumulated OCI81M98M60M490M(180.59M)
Other Stockholders Equity00000
Minority Interest00000
Total Equity22.2B27.28B31.61B36.7B5.83B
Total Debt425M597M770M1.03B5.43B
Net Debt(8.53B)(9.3B)(14.1B)(8.83B)3.71B

Genmab A/S

NASDAQ:GMAB

Intrinsic Alpha fair value

Locked

Current Price

$50.97

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.